Skip to Content
Merck
CN

755982

Lutetium

dendritic pieces, purified by distillation, 99.99% trace metals basis

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
Lu
CAS Number:
Molecular Weight:
174.97
UNSPSC Code:
12352300
PubChem Substance ID:
EC Number:
231-103-0
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

99.99% trace metals basis

form

dendritic pieces

purified by

distillation

resistivity

54 μΩ-cm, 20°C

bp

3402 °C (lit.)

mp

1663 °C (lit.)

density

9.84 g/mL at 25 °C (lit.)

SMILES string

[Lu]

InChI

1S/Lu

InChI key

OHSVLFRHMCKCQY-UHFFFAOYSA-N



Storage Class

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Xuejuan Wang et al.
European journal of nuclear medicine and molecular imaging, 39(12), 1876-1885 (2012-08-29)
Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled peptides is of interest for tumour localization, staging, therapy follow-up and targeted radionuclide therapy. The peptides used clinically are exclusively agonists, but recently we have shown that the radiolabelled somatostatin-based
Ksenija R Kumrić et al.
Journal of separation science, 35(18), 2390-2398 (2012-09-22)
In this study, the mass transport resistance in liquid-phase microextraction (LPME) in a single hollow fiber was investigated. A mathematical model has been developed for the determination of the overall mass transfer coefficient based on the acceptor phase in an
Rebecca A Dumont et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 762-769 (2013-03-16)
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer and is an attractive target for radionuclide therapy. In addition, inhibition of the protein kinase mammalian target of rapamycin (mTOR) has been shown to sensitize various cancer cells to the